학술논문
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC
Document Type
Article
Author
Akinboro, O.; Larkins, E.; Pai-Scherf, L.H.; Mathieu, L.N.; Ren, Y.; Cheng, J.; Fiero, M.H.; Fu, W.; Bi, Y.; Mishra-Kalyani, P.S.; Zirkelbach, J.F.; Li, H.; Zhao, H.; He, K.; Helms, W.S.; Chuk, M.K.; Wang, M.; Bulatao, I.; Herz, J.; Osborn, B.L.; Xu, Y.; Liu, J.; Gong, Y.; Sickafuse, S.; Cohen, R.; Donoghue, M.; Pazdur, R.; Beaver, J.A.; Singh, H.; Kalavar, S.; Jafri, S.
Source
In: Clinical Cancer Research . (Clinical Cancer Research, 1 June 2022, 28(11):2221-2228)
Subject
Language
English
ISSN
15573265
10780432
10780432